

**Special Thematic Issue for Anti-Cancer Agents in Medicinal Chemistry
Tyrosine Kinase Inhibitors Drugs in the Treatment of Cancer**

Guest Editors: Jingkun Fang, Yingjun Zhang

Aims & Scope:

It is well known that the tyrosine phosphorylation is a crucial process in the development of cancer. Tyrosine kinase inhibitors (TKIs) are widely applied to disrupt this signal transduction process in the treatment of cancer. The achievements related to this field are very impressive and many studies are underway. The purpose of this special issue proposal is to summarize recent advances in the developing, synthesis, modification and theoretical study of Tyrosine Kinase Inhibitors Drugs in the Treatment of Cancer.

Keywords:

Tyrosine kinase inhibitors, Cancer Treatment, and Drug development

Subtopics:

The subtopics to be covered within this issue are listed below:

Topic 1. Newly developed Tyrosine Kinase Inhibitors Drugs for cancer therapy.

Topic 2. Novel synthetic methods or modification ways for Tyrosine Kinase Inhibitors Drugs.

Topic 3. Important theoretical study of Tyrosine Kinase Inhibitors Drugs.

Topic 4. Mechanism of Tyrosine Kinase Inhibitors Drugs for cancer therapy.

Author Details:

The potential contributors are listed below:

Author 1: Eric M. Scholar; Pharmacology and Experimental Neuroscience (E.M.S.), University of Nebraska Medical Center, Omaha, Nebraska; escholar@unmc.edu; h-

index: 18

Author 2: Tamura, Tomohide; St Lukes Int Hosp, Thorac Ctr, Chuo Ku, Tokyo 1048560, Japan. tamuratomohide@gmail.com; h-index 44

Author 3: Kim, Tae Min; Seoul Natl Univ Hosp, Dept Internal Med, 101 Daehak Ro, Seoul 03080, South Korea. cri304@snu.ac.kr; h-index 12

Author 4: Dussault, Isabelle; Amgen Inc, Dept Oncol Res, Thousand Oaks, CA 91320 USA. idussaul@amgen.com; h-index 23

Author 5: Wang, Jun; Jinan Command Peoples Liberat Army, Gen Hosp, Dept Oncol, Shifan St 25, Jinan 250031, Peoples R China. ggjun2005@126.com; h-index 14

Author 6: Lu, Shun; Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Shanghai Lung Canc Ctr, 241 Huaihai West Rd, Shanghai 200030, Peoples R China. shunl1964@gmail.com; h-index 27

Schedule:

Manuscript submission deadline: 31st March 2020

Peer Review Due: 20th April 2020

Revision Due: 10th May 2020

Announcement of acceptance by the Guest Editors: 20th May 2020

Final manuscripts due: 31st May 2020

Contacts:

Guest Editors:

Dr. Jingkun Fang

Affiliation: School of Chemical Engineering, Nanjing University of Science and Technology, Nanjing 210094, China

E-mail: fjk@njust.edu.cn

Dr. Yingjun Zhang

Affiliation: State Key Laboratory of Anti-Infective Drug Development, Sunshine

Lake Pharma Co., Ltd, Dongguan 523871, China

E-mail: ZhangYingjun@hec.cn